Polymerised oestrogen provides neuroprotection in pre-clinical study
The polymerised form of oestrogen has shown success in mice at preventing further damage to the spinal cord after injury.
List view / Grid view
The polymerised form of oestrogen has shown success in mice at preventing further damage to the spinal cord after injury.
Promising results have been shown in an animal model of Alzheimer's disease treated with zinc finger protein transcription factors.
A synthetic cannabinoid has shown promise as a treatment for involuntary tremors by activating astrocytes in mouse models.
Scientists have developed a model of the early stages of Alzheimer's disease in rhesus macaques to better test new treatments.
Researchers have reported that nano-micelles can be used to efficiently deliver CRISPR-Cas9 to edit genes in the brains of mice.
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.
Researchers have used artificial intelligence to screen 80 FDA-approved drugs and reveal which could be used as Alzheimer's treatments.
Using X-ray crystallography and cryo-electron microscopy, researchers have elucidated the structure of the SARM1 protein, a target for neurodegeneration.
In pre-clinical studies, a novel treatment decreased plaque formation, meaning it could be used to prevent Alzheimer's disease.
Researchers have found that the spasmolytic drug hymecromone can suppress astrocyte inflammatory responses, meaning it could be used to combat Alzheimer's disease.
Scientists have developed a compound that stops the degeneration of upper motor neurons, a contributor to amyotrophic lateral sclerosis (ALS).
A version of the FOXO3 gene can protect brain stem cells from stress during ageing, according to a new study.
An enzyme in fruit fly larvae plays a role in reactivating neural stem cells, which could explain how some neurodevelopmental disorders occur.
Researchers have discovered that all childhood neuroblastomas come from sympathoblasts, making them a drug target to treat the condition.
In this article, we explore the findings of a study that suggests a newly identified pathway, the Drp1-HK1-NLRP3 signalling axis, could be a promising target for therapies to prevent Alzheimer’s disease progression.